A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer
Hideki Tomimoto(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Yasuhiko Nishioka(Tokushima University), Hiroya Tada(Tokushima University), Eiji Takeuchi(Higashi Nagoya National Hospital), Masahiko Azuma(Tokushima University), Hisatsugu Goto(Tokushima University), Tsutomu Shinohara(National Hospital Organization Kochi National Hospital), Akihiko Yamamoto, Masaki Hanibuchi(Tokushima University), Hiroyuki Doi, Takanori Kanematsu(Matsuyama Red Cross Hospital), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Yoshio Okano(Toneyama National Hospital), Fumitaka Ogushi(Tokushima University), Akiyoshi Yamamoto(Takamatsu Red Cross Hospital), Seiji Yano(Kanazawa University Hospital)
Cited by 3
Related Papers
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175